Published on: 
Supplements and Featured Publications, Targeting HPV: The Power of Prevention, Volume 12, Issue 17 Suppl

Continuing Medical Education Accreditation

AMA PRA Category 1 CME credit(s)

The University of Cincinnati College of Medicine designates this educational activity for a maximum of two (2) â„¢. Physicians should only claim credit commensurate with the extent of their participation in this activity.

The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians.

Continuing Pharmacy Education Accreditation

Pharmacy Times

/Ascend Media Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-999-06-018-H01.


After reading "Targeting HPV: The Power of Prevention," complete the program evaluation and select the 1 best answer to each of the following questions. A statement of continuing education hours will be mailed to those who successfully complete (with a minimum score of 70%) the examination at the conclusion of the program.

1. The highest prevalence of human papillomavirus (HPV) in women is seen:

  • at menopause.
  • in large cities.

2. Factors associated with an increased risk of HPV in women include all of the following except:

  • smoking.
  • extended use of oral contraceptives.

3. Which statement is true concerning different strains of HPV?

  • Only 4 strains have been identified as high risk based on their association with cervical or other anogenital cancer.
  • Low-risk HPV can cause genital warts.

4. Concerning cervical cancer epidemiology:

  • the incidence reported in cities with screening programs may be higher than the actual overall incidence.
  • almost 20 000 new cases are reported in the United States annually.

5. Concerning cervical cancer pathology and clinical presentation:

  • preinvasive dysplasia is asymptomatic.
  • the most common symptoms of invasive cervical cancer are dyspareunia, dysmenorrhea, and dysuria.

6. Which statement is true concerning the Papanicolaou (Pap) test?

  • Among all Pap tests performed in the United States, 40% are abnormal, and 10% of abnormal cases are cervical cancer.
  • The chief weakness of the test is a high rate of false-positives.

7. Which statement is true concerning tests to detect HPV?

  • Compared with the Pap test, HPV testing is less sensitive but more specific.
  • HPV testing is most useful for cervical specimens showing ASC-US.

8. Vaccination against HPV uses:

  • live attenuated HPV.
  • bioengineered synthetic viral ribonucleic acid.

9. Anti-HPV vaccine efficacy is demonstrated by reductions in the incidence of:

  • either persistent type-specific HPV infection or moderate- to high-grade cervical neoplasia.
  • cervical neoplasia without regard to HPV infection.

10. Which statement is true concerning anti-HPV vaccines?

  • Clinical trials show efficacy rates approaching 100% for both vaccines.
  • Cervarix has been shown to produce larger and more sustained antibody responses because of its unique adjuvant.

11. Which statement is true concerning vaccine protection against cervical cancer?

  • Reduction in the incidence of genital warts is accepted as a surrogate marker for reduction in cervical cancer.
  • Reductions in cervical cancer incidence cannot be demonstrated without long-term extension studies.

12. The duration of immunogenicity after vaccination is believed to be approximately:

  • 5 years.
  • 15 to 20 years.

13. Which statement is true concerning the expected cost impact of anti-HPV vaccination?

  • Vaccination programs that include men are slightly more cost-effective than programs for women only.
  • All of the above

14. The condition most consistently correlated with HPV infection is:

  • cervical cancer.
  • fallopian tube stricture and scarring.

15. Among parents who reject HPV vaccination for their children, the most common reason is the belief that:

  • vaccination cannot prevent HPV.
  • HPV is caused mainly by intravenous drug abuse.

16. Recommendations for HPV vaccination include:

  • vaccination of girls aged 11 to 12.
  • vaccination contraindicated in people who are already sexually active.

17. HPV vaccination protects against:

  • all pathogenic strains of HPV.
  • a limited number of pathogenic or oncogenic strains of HPV.

18. The least common false belief about vaccination in children is that:

  • vaccines can cause autism.
  • vaccination is a fraud.

19. The cost of HPV vaccination is:

  • comparable to the cost of most other recommended vaccines.
  • all of the above

20. Barriers to HPV vaccination in adolescents include:

  • the lack of other vaccines aimed at adolescents.
  • the belief that a 1-year period of sexual abstinence is required following HPV vaccination.